Use of Different Treatment Care Methods in Patients With Dementia Associated With Alzheimer's Disease

NCT ID: NCT00283725

Last Updated: 2013-01-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

573 participants

Study Classification

OBSERVATIONAL

Study Start Date

2003-06-30

Study Completion Date

2006-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this observational study is to examine patterns of treatment care for patients with Alzheimer's disease (AD) in a real-world arena and to examine the association with different outcomes for patients and informal caregivers.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a 2-year, multicenter, prospective (look forward using periodic observations collected predominantly following patient enrollment), longitudinal (it is a co relational research study that involves repeated observations of the same variables over long periods of time), and observational study. The objective of this study is to examine the patients with mild and moderate AD who are currently being treated with different treatment care methods in real-world settings. Doctors will not be provided medication or asked to treat their patients with any particular treatment. The effect of the different management strategies on cognition, activities of daily living, and behavior of the patients will be evaluated, and data on the informal caregiver burden will be assessed. Data on the utilization of health and social care services by the patient and the primary informal caregiver, including admission of the patient to an assisted living facility or nursing home will be assessed. The doctor's assessment of clinical global impression and adverse events will also be documented. Data will be collected from the doctors at baseline and at 6, 12, and 24 months, and from the caregivers at baseline and 6, 12, 18, and 24 months. The medication dosage and administration is based upon the doctors' prescription, individualized for the patient and not dictated by the protocol.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dementia Alzheimer's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Galantamine

No intervention

Intervention Type OTHER

Patients will be prescribed either galantamine or no AD treatment (ie, neither an acetylcholinesterase inhibitor \[AChEI\] nor memantine).

No Alzheimer's disease (AD) treatment

No intervention

Intervention Type OTHER

Patients will be prescribed either galantamine or no AD treatment (ie, neither an acetylcholinesterase inhibitor \[AChEI\] nor memantine).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

Patients will be prescribed either galantamine or no AD treatment (ie, neither an acetylcholinesterase inhibitor \[AChEI\] nor memantine).

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have a physician-based diagnosis of mild to moderate Alzheimer's disease (Mini-Mental State Examination \[MMSE\] score between 10-24)
* Must be living at home or in a facility for the elderly (eg, assisted living), who live with or have frequent visits from a friend or relative (caregiver) or with a behavioral symptom (eg, as agitation or wandering)
* Have no plan to change the current treatment plan for at least 90 days

Exclusion Criteria

* Have been using an acetylcholinesterase inhibitor or memantine currently but have used one in the past 30 days
* Must be residing in or planning to move to a nursing home within the next 90 days or patients participating in another clinical trial
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ortho-McNeil Neurologics, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ortho-McNeil Neurologics, Inc. Clinical Trial

Role: STUDY_DIRECTOR

Ortho-McNeil Neurologics, Inc.

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GALALZ4004

Identifier Type: OTHER

Identifier Source: secondary_id

GAL-OUT-065

Identifier Type: OTHER

Identifier Source: secondary_id

CR004636

Identifier Type: -

Identifier Source: org_study_id

NCT01712932

Identifier Type: -

Identifier Source: nct_alias

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Optimizing Dementia Care
NCT02585232 COMPLETED NA